{
    "title": "Alzheimer's dementia: current data review.",
    "doc_id": "22397284",
    "writer": "Uzun S",
    "year": "2011",
    "summary": "Cholinesterase inhibitors -donepezil, rivastigmine and galantamine are considered to be the first line pharmacotherapy for mild to moderate Alzheimer's disease. Currently, no effective pharmacologic interventions have been researched enough to support their u â€¦",
    "abstract": "The review focuses on current data on Alzhemier's dementia, a clinical syndrom characterised with acquired deterioration of cognitive functioning and emotional capacities, which impaires everyday activity and quality of life. Alzheimer's dementia is the most common type of dementia in clinical surveys. The diagnosis of Alzheimer's dementia is primarily based on symptoms and signs and memory impairment is clinically most significant. Cholinesterase inhibitors -donepezil, rivastigmine and galantamine are considered to be the first line pharmacotherapy for mild to moderate Alzheimer's disease. Currently, no effective pharmacologic interventions have been researched enough to support their use in prevention of Alzheimer's dementia. Studies suggest that healthy lifestyle, ongoing education, regular physical activity, and cholesterol control, play a role in prevention of Alzheimer's dementia.",
    "link": "https://pubmed.ncbi.nlm.nih.gov/22397284/",
    "clean_text": "alzheimer s dementia current data review cholinesterase inhibitors donepezil rivastigmine and galantamine are considered to be the first line pharmacotherapy for mild to moderate alzheimer s disease currently no effective pharmacologic interventions have been researched enough to support their u the review focuses on current data on alzhemier s dementia a clinical syndrom characterised with acquired deterioration of cognitive functioning and emotional capacities which impaires everyday activity and quality of life alzheimer s dementia is the most common type of dementia in clinical surveys the diagnosis of alzheimer s dementia is primarily based on symptoms and signs and memory impairment is clinically most significant cholinesterase inhibitors donepezil rivastigmine and galantamine are considered to be the first line pharmacotherapy for mild to moderate alzheimer s disease currently no effective pharmacologic interventions have been researched enough to support their use in prevention of alzheimer s dementia studies suggest that healthy lifestyle ongoing education regular physical activity and cholesterol control play a role in prevention of alzheimer s dementia"
}